Asuragen to Present at 2019 ACMG Annual Clinical Genetics Meeting
New products for analysis of genes associated with Huntington’s disease and spinal muscular atrophy to be featured
AUSTIN, Texas--(BUSINESS WIRE)-- Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy-to-use products for complex testing in genetics and oncology, will showcase its new genetics products at the upcoming ACMG Annual Clinical Genetics Meeting on April 2-6 in Seattle, Washington. The company’s most recent portfolio additions, the AmplideX® PCR/CE HTT* and PCR/CE SMN1/2* Kits, will be featured in a pair of poster presentations highlighting their rapid turnaround compared to standard methodologies, reliable performance, and harmonized testing workflows.
Asuragen’s posters will be presented during the poster session on Thursday, April 4 from 10:00 – 11:30 a.m.
Two-site Evaluation of a Rapid, Multiplexed PCR/CE Assay for Assessment of Spinal Muscular Atrophy SMN1 and SMN2 Copy Number Status (Stela Filipovic-Sadic)
Evaluation of the AmplideX® PCR/CE HTT Kit for the Rapid and Accurate Genotyping of CAG Repeat Expansions (Darshana Patel)
“With our rapidly growing product portfolio, we continue to provide simple, scalable, and easy-to-implement testing solutions for challenging genomic targets, many of which are implicated in neurodegenerative and neurodevelopmental diseases,” said Matthew McManus, MD, PhD, president and CEO of Asuragen. “Our proprietary AmplideX chemistries allow analysis of these genes by laboratories everywhere and can help accelerate clinical research to advance our understanding of these debilitating conditions.”
The company will also have a presence at booth #828 during the conference.
* For research use only. Not for use in diagnostic procedures.
Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190326005276/en/
SVP, Corporate Development & CFO
Source: Asuragen, Inc.